AgeX Therapeutics

Last updated
AgeX Therapeutics, Inc.
Type Public
AMEX:  AGE
Industry Biotechnology, aging research
Founded2017
Founder Michael D. West
Headquarters Alameda, California
Key people
Michael D. West
(CEO)
Gregory Bailey
(chairman)
Website www.agexinc.com

AgeX Therapeutics, Inc. (commonly abbreviated as AgeX Therapeutics or simply AgeX) is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West, initially as a subsidiary of BioTime, Inc. with backing from British billionaire investor Jim Mellon and others. [1] [2] [3] [4]

The chairman is Gregory Bailey, who was an early backer and board member of Medivation until its acquisition by Pfizer in 2016 for $14 billion. [3] [5]

In January 2020, AgeX Therapeutics announced a research collaboration with a Japanese biopharma company utilizing AgeX's UniverCyte technology platform. [6]

Related Research Articles

Pfizer American multinational pharmaceutical corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German immigrants, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

Takeda Pharmaceutical Company Pharmaceutical company in Asia

The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and President of Takeda.

AstraZeneca British-Swedish pharmaceutical company

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford-AstraZeneca COVID-19 vaccine.

Sanofi S.A. is a French multinational healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

Astex Pharmaceuticals ("Astex") is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.

Celgene American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

Boehringer Ingelheim German pharmaceutical company

C.H. Boehringer Sohn AG & Ko. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

Astellas Pharma Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

Nuvelo Inc. was a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. On January 27, 2009, the company was acquired by ARCA Biopharma, Inc. in a reverse takeover transaction.

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Calico Life Sciences LLC is an American research and development biotech company founded on September 18, 2013, by Bill Maris and backed by Google with the goal of combating aging and diseases of aging. In Google's 2013 Founders Letter, Larry Page described Calico as a company focused on "health, well-being, and longevity" and the company's name is an acronym for "California Life Company."

Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.

Juno Therapeutics American biopharmaceutical company

Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Roivant Sciences is a healthcare company focused on applying technology to drug development. Roivant builds subsidiary biotech and healthcare technology companies. Roivant was founded by Vivek Ramaswamy in 2014.

James Mellon is a British businessman.

Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby DNA sequences can be modified even more precisely compared to previous methods.

Cambrian Biopharma ("Cambrian") is a New York City-based multi-asset longevity biotechnology company that develops and funds therapeutics aimed at lengthening healthspan. It studies the biological basis of aging, such as cellular wear and tear or mutations in DNA, and funds related treatments to slow the processes.

References

  1. Lawton, Graham (April 24, 2019). "Anti-ageing drugs are coming that could keep you healthier for longer". New Scientist .
  2. Wang, Brian (December 16, 2017). "AgeX to develop powerful regenerative and anti-aging treatments". Next Big Future.
  3. 1 2 Carroll, John (July 26, 2017). "British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart". Endpoints News.
  4. "Juvenescence aims to tap longevity 'money fountain'". Financial Times . June 11, 2018.
  5. Pollack, Andrew; Picker, Leslie (August 22, 2016). "Pfizer to Buy Cancer Drug Maker in $14 Billion Deal". New York Times .
  6. "AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells". Yahoo! Finance . 2020-01-29. Archived from the original on 2020-02-24.